The lawsuit, filed by the Rosen Law Firm, centers on claims that Zoetis executives issued false statements about the company's growth trajectory and product adoption rates. According to the complaint, the firm failed to disclose significant challenges facing its flagship offerings. Specifically, the suit alleges that prescription growth for the canine pain treatment Librela slowed as clinicians reacted to FDA warnings regarding potential neurological complications. Furthermore, the filing claims that the company’s Simparica Trio and dermatology brands, Apoquel and Cytopoint, faced mounting pressure from lower-priced competitors, resulting in a loss of market share that was not properly communicated to the market.

Those who acquired shares during the designated period may participate in the action through a contingency fee arrangement, meaning no out-of-pocket costs are required for legal representation. While the court has not yet certified a class, investors retain the right to select their own counsel or remain absent class members. Interested parties can contact attorney Phillip Kim to review their potential involvement before the July 27 deadline.